Physician profile
David A Rosnack
NPI 1215906771
$1,533.18
in general payments reported to CMS, 2019-2025
18 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $30.73 · 2021: $200 · 2022: $104 · 2023: $235 · 2024: $315 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.15 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $334.94 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $273.63 | 2019-2024 | Lokelma |
| Travere Therapeutics, INC. | $268.43 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $161.66 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $131.00 | 2021-2023 | Acthar |
| Vifor Pharma, INC. | $73.68 | 2023-2025 | Veltassa |
| Amgen INC. | $52.24 | 2019-2024 | Tavneos |
| Akebia Therapeutics INC | $46.67 | 2024 | Auryxia, Vafseo |
| Corcept Therapeutics | $24.49 | 2025 | Korlym |
| Opko Pharmaceuticals, LLC | $23.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.44 | 2024 | |
| Ardelyx, INC. | $21.36 | 2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $20.44 | 2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $18.41 | 2019 | |
| Daiichi Sankyo INC. | $17.62 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.06 | 2024 | Illumisite |
| Apellis Pharmaceuticals, INC. | $15.62 | 2025 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosnack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.